EDIT - Editas Medicine, Inc.
| Previous Close | 26.21 |
| Open | 26.32 |
| Bid | 26.14 x 1000 |
| Ask | 26.06 x 900 |
| Day's Range | 25.90 - 26.78 |
| 52 Week Range | 17.80 - 45.02 |
| Volume | 648,314 |
| Avg. Volume | 792,832 |
| Market Cap | 1.242B |
| Beta (3Y Monthly) | 3.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.65 |
| Earnings Date | Mar 4, 2019 - Mar 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.71 |
- GlobeNewswire•12 hours ago
Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10)
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data demonstrating the pharmacology and specificity of EDIT-101, an experimental, CRISPR genome editing medicine being investigated for the treatment of Leber congenital amaurosis 10 (LCA10), a genetically-driven form of blindness. “We are thrilled Nature Medicine published our paper sharing the comprehensive set of pre-clinical data for EDIT-101 and our approach to creating CRISPR-based genome editing medicines,” said Charles Albright, Ph.D., Chief Scientific Officer, Editas Medicine. “The research presented in this important manuscript provided the foundation for our recently accepted Investigational New Drug (IND) application for EDIT-101 to treat LCA10, bringing us closer to the clinic and our goal of realizing the full potential of genome editing.
- Zacks•3 days ago
Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know
Editas Medicine (EDIT) closed at $26.03 in the latest trading session, marking a -0.69% move from the prior day.
- Motley Fool•3 days ago
4 Gene-Editing Technologies That Could Replace CRISPR
The future of medicine involves the precise engineering of human cells. Turns out, that future may not include that promising CRISPR technique.
- ACCESSWIRE•7 days ago
Today's Research Reports on Trending Tickers: Exelixis and Editas Medicine
NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...
- Zacks•10 days ago
Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know
Editas Medicine (EDIT) closed at $26.20 in the latest trading session, marking a -0.8% move from the prior day.
- Motley Fool•11 days ago
Here's Why Editas Medicine Lost 16.6% in December
The gene-editing pioneer surprised investors with the departure of its CFO, but there doesn't seem to be any cause for alarm.
- Motley Fool•11 days ago
The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29%
The three gene-editing pioneers had mixed results last year, but each has big plans for the year ahead.
- Motley Fool•12 days ago
4 Reasons Editas Medicine's Future Looks Really Bright
Forget the biotech's stock performance last year. The future should provide a much better story.
- American City Business Journals•12 days ago
CRISPR cadre: Check out the 12 Mass. companies exploring gene editing
Pharmaceutical giants like Bayer and Novartis have dipped their toes into gene editing through collaborations, while others are adopting it in their own laboratories.
- Zacks•13 days ago
Radius Exceeds 2018 Financial Guidance, Provides Updates
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
- Zacks•14 days ago
Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other updates.
- Zacks•14 days ago
Has Editas Medicine (EDIT) Outpaced Other Medical Stocks This Year?
Is (EDIT) Outperforming Other Medical Stocks This Year?
- Zacks•14 days ago
Editas Medicine, YY, Intel, Advanced Micro Devices and NVIDIA highlighted as Zacks Bull and Bear of the Day
Editas Medicine, YY, Intel, Advanced Micro Devices and NVIDIA highlighted as Zacks Bull and Bear of the Day
- Zacks•14 days ago
Aerie's Rhopressa Succeeds in Study on Japanese Patients
Aerie (AERI) announces encouraging top-line results from its pilot phase II study of netarsudil ophthalmic solution in a Japan.
- Zacks•15 days ago
Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.
- GlobeNewswire•15 days ago
Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference
In a presentation to investors on Wednesday, January 9, 2019, at 9:00 a.m. PST at the 37th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc. (EDIT) President and CEO Katrine Bosley will discuss the Company’s plans to initiate patient screening and patient dosing for EDIT-101. Additionally, she will outline progress in the Company’s program for the treatment of sickle cell disease, including data that support opportunities to develop best-in-class, durable medicines for hemoglobinopathies. Ms. Bosley will also detail the Company’s progress on “EM22,” the Company’s long-range goals through the year 2022 and vision for advancing Editas Medicine as a leading genome editing company, including sharing details on advancements in its ocular and engineered cell medicine programs.
- Zacks•17 days ago
Jazz Inks Deal with Codiak to Develop Exosome Therapeutics
Jazz (JAZZ) collaborates with Codiak for research, development and commercialization of exosome therapeutics to treat cancer.
- Investor's Business Daily•17 days ago
These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy
Crispr Therapeutics popped Friday after the FDA said it would expedite review of its Vertex Pharmaceuticals-partnered gene-editing sickle cell disease treatment.
- Zacks•19 days ago
Novo Nordisk Boasts Strong Diabetes Presence and Pipeline
Novo Nordisk (NVO) has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin.
- Zacks•19 days ago
Sarepta (SRPT) Inks Deal With Aldevron for Plasmid DNA Supply
Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.
- GlobeNewswire•20 days ago
Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2019 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a.
- CNBC Videos•13 days ago
Editas CEO Katrine Bosley: We take the responsibility of ...
Editas Medicine president and CEO Katrine Bosley discusses her company's gene editing technology and the future of medicine.
- Yahoo Finance Video•24 days ago
Biotech markets could be ‘very promising’ in 2019
Even though biotech markets are “down big this year,” Managing Director Mitchell Ng of Thessalus Capital says that there are “specific industries within the healthcare sector that are very promising,” such as gene editing companies. Yahoo Finance’s Alexis Christoforous speaks to him about the future for biotech in 2019.
